- Home
- UTHR vs IP Comparison
UTHR vs IP Comparison
Compare UTHR & IP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- IP
- Stock Information
- Founded
- UTHR 1996
- IP 1898
- Country
- UTHR United States
- IP United States
- Employees
- UTHR N/A
- IP N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- IP Paper
- Sector
- UTHR Health Care
- IP Basic Materials
- Exchange
- UTHR Nasdaq
- IP Nasdaq
- Market Cap
- UTHR 20.7B
- IP 24.6B
- IPO Year
- UTHR 1999
- IP N/A
- Fundamental
- Price
- UTHR $448.47
- IP $46.49
- Analyst Decision
- UTHR Buy
- IP Buy
- Analyst Count
- UTHR 15
- IP 8
- Target Price
- UTHR $459.60
- IP $56.14
- AVG Volume (30 Days)
- UTHR 846.4K
- IP 3.8M
- Earning Date
- UTHR 10-29-2025
- IP 10-30-2025
- Dividend Yield
- UTHR N/A
- IP 3.98%
- EPS Growth
- UTHR 17.94
- IP N/A
- EPS
- UTHR 25.63
- IP N/A
- Revenue
- UTHR $3,077,800,000.00
- IP $21,934,000,000.00
- Revenue This Year
- UTHR $13.71
- IP $45.44
- Revenue Next Year
- UTHR $5.72
- IP $4.10
- P/E Ratio
- UTHR $17.38
- IP N/A
- Revenue Growth
- UTHR 17.62
- IP 18.13
- 52 Week Low
- UTHR $266.98
- IP $43.27
- 52 Week High
- UTHR $459.48
- IP $60.36
- Technical
- Relative Strength Index (RSI)
- UTHR 65.25
- IP 46.83
- Support Level
- UTHR $415.00
- IP $45.50
- Resistance Level
- UTHR $459.40
- IP $47.33
- Average True Range (ATR)
- UTHR 13.47
- IP 0.94
- MACD
- UTHR -1.34
- IP 0.10
- Stochastic Oscillator
- UTHR 71.49
- IP 69.65
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About IP International Paper Company
International Paper manufactures packaging products and cellulose fibers. It accounts for roughly one-third of the North American corrugated packaging market. The company also has a substantial presence in Europe following its acquisition of DS Smith. International Paper serves a variety of end markets, including industrial, consumer products, and manufacturing.